References
1. Lee JI, Park HJ, Lee JY, Cho BK. A case of pyoderma gangrenosum with ulcerative colitis treated with mesalazine. Ann Dermatol. 2010; 22:422–425.
2. Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011; 165:1244–1250.
3. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996; 34:395–409. quiz 410-412.
4. Mlika RB, Riahi I, Fenniche S, et al. Pyoderma gangrenosum: a report of 21 cases. Int J Dermatol. 2002; 41:65–68.
5. Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol. 2017; 53:413–427.
6. Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol. 2018; 14:225–233.
7. Byeon YM, Lee J, Lee SJ, et al. Peritonsillar involvement in pyoderma gangrenosum associated with ulcerative colitis. Intest Res. 2014; 12:153–156.
8. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015; 21:1982–1992.
9. Herberger K, Dissemond J, Hohaus K, Schaller J, Anastasiadou Z, Augustin M. Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. Br J Dermatol. 2016; 175:1070–1072.
10. Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015; 350:h2958.